Drugs Containing Excipient (Inactive Ingredient) 1,2-BUTANEDIOL

Generic drugs containing 1,2-BUTANEDIOL excipient

Company	Ingredient	NDC	Excipient
Qingdao Kuajie Online Electronic Technology Co Ltd	minoxidil 5%	84033-002	1,2-BUTANEDIOL

1,2-Butanediol Market Dynamics and Financial Trajectory

Last updated: August 24, 2026

1,2-Butanediol, also known as 1,2-butylene glycol, is a specialty diol used as a solvent, humectant, plasticizer, and formulation aid. Its commercial market is small and fragmented compared with propylene glycol, glycerin, polyethylene glycol, and 1,3-butanediol. Public financial disclosures do not isolate 1,2-butanediol revenue, so its financial trajectory must be assessed through end-use demand, feedstock economics, regulatory qualification, and supplier pricing rather than reported market capitalization or segment revenue.

The central commercial issue is product identity. 1,2-butanediol is CAS 584-03-6, while 1,3-butanediol is CAS 107-88-0. Market reports often combine both materials under “butylene glycol,” creating a material risk of overstated market-size estimates.[1][2]

What is 1,2-butanediol and how is it used?

1,2-Butanediol is a four-carbon aliphatic diol with the molecular formula C4H10O2 and molecular weight of 90.12 g/mol. It is a colorless liquid with hydroxyl groups on adjacent carbon atoms. The molecule exists in stereoisomeric forms because the carbon at position 2 is chiral.[1]

Its principal functional roles are:

Function	Formulation relevance
Solvent	Dissolves selected active ingredients, fragrances, and co-formulants
Humectant	Retains water in topical and personal-care formulations
Co-solvent	Supports aqueous-organic systems
Plasticizer	Modifies flexibility in selected polymer systems
Intermediate	Used in chemical synthesis and specialty-material production

The pharmaceutical opportunity is narrower than the cosmetics and industrial opportunity. Pharmaceutical adoption depends on impurity limits, residual catalyst control, stereochemical composition, toxicology, container compatibility, and lot-to-lot consistency. A material sold as technical-grade butylene glycol cannot be assumed to qualify for pharmaceutical use.

How large is the 1,2-butanediol market?

A defensible standalone global market value for 1,2-butanediol is not available from public company filings or major regulatory databases. Published market estimates that cite “butylene glycol” often include 1,3-butanediol, mixtures, cosmetic-grade material, and sometimes unrelated butanediol derivatives.

The market is best characterized as a niche specialty-chemical segment with three economic layers:

1. Bulk or semi-bulk industrial material.
2. High-purity material for pharmaceutical, cosmetic, food-contact, or analytical applications.
3. Small-volume research and formulation grades sold through laboratory distributors.

The high-purity segment generates a disproportionate share of supplier margin. Pharmaceutical customers generally buy on specification rather than lowest nominal price. Qualification costs, audit requirements, documentation, and change-control obligations can make a qualified supplier commercially difficult to replace.

Why market estimates vary

Market reports may differ because they:

• Combine 1,2-butanediol with 1,3-butanediol.
• Include derivatives rather than the neat diol.
• Count cosmetic formulations rather than raw-material sales.
• Treat laboratory catalog sales as industrial revenue.
• Apply different definitions of pharmaceutical-grade material.
• Use production capacity instead of realized sales.

Any investment model should therefore separate CAS 584-03-6 from CAS 107-88-0 and exclude products marketed only as generic “butylene glycol.”

What are the main demand drivers?

Pharmaceutical formulation demand

The pharmaceutical demand case is based on functional substitution. 1,2-Butanediol can be evaluated where a developer needs a polyol solvent or humectant with a different volatility, polarity, viscosity, or sensory profile from propylene glycol and glycerin.

Potential applications include:

• Topical liquids, gels, creams, and ointments.
• Oral liquid or semi-solid formulations where toxicological and regulatory requirements are satisfied.
• Drug-delivery systems requiring a water-miscible co-solvent.
• Excipients for poorly water-soluble compounds.
• Process solvents and formulation-development intermediates.

The limiting factor is not chemical functionality. It is regulatory and formulation qualification. A developer must establish that the specific material, grade, impurity profile, and use level are acceptable for the intended route of administration.

Cosmetics and personal care

Cosmetics are a more accessible demand channel because humectancy, solvency, and skin-feel performance can justify substitution. The segment also tolerates a broader range of supplier specifications than injectable or oral pharmaceutical products, subject to regional cosmetic regulations.

Competition is intense. Formulators can often select propylene glycol, glycerin, 1,3-butanediol, pentylene glycol, caprylyl glycol, or polyethylene glycol products. A 1,2-butanediol supplier must therefore establish a measurable advantage in sensory profile, preservative support, solvency, irritation profile, or cost.

Industrial and specialty chemical uses

Industrial demand provides a volume base but generally has lower margins than pharmaceutical-grade sales. Uses may include resin modification, solvent systems, coatings, and chemical intermediates. These outlets can absorb off-specification or non-pharmaceutical material, improving manufacturing economics for producers that operate integrated purification systems.

How does 1,2-butanediol compare with competing excipients?

Attribute	1,2-butanediol	Propylene glycol	Glycerin	1,3-butanediol	PEG 400
Market maturity	Niche	Very high	Very high	High in cosmetics and specialty chemicals	High
Pharmaceutical familiarity	Limited relative to substitutes	Extensive	Extensive	Application-dependent	Extensive
Main advantage	C4 diol functionality and formulation flexibility	Established safety and supply	Strong humectancy and broad acceptance	Cosmetic and formulation versatility	Solvency and molecular-weight range
Main weakness	Limited regulatory and commercial familiarity	Possible irritation at high exposure	High viscosity and tack	Confusion with 1,2-isomer	Batch and molecular-weight distribution considerations
Substitution risk	High	Baseline comparator	High	High	High

Propylene glycol is the strongest direct commercial substitute because it has broad pharmaceutical acceptance, global supply, and extensive formulation precedent. Glycerin competes where humectancy and low cost dominate. 1,3-butanediol is a particularly important source of market confusion and may be more commercially established in personal care.

What is the FDA regulatory status of 1,2-butanediol?

1,2-Butanediol does not have a drug-style FDA approval, exclusivity period, or standalone pharmaceutical marketing authorization. Excipients are generally not approved as independent finished drugs. Their regulatory position depends on use in a specific drug product, route, concentration, quality specification, and supporting safety package.

The FDA Inactive Ingredient Database is the key public reference for prior use of excipients in approved drug products. Presence in the database can support regulatory precedent, but it does not create a general approval for every route, dose, formulation, or supplier.[3]

For a pharmaceutical-grade 1,2-butanediol program, the commercial documentation package would normally need to address:

• Identity and assay.
• Water content and acidity.
• Related glycols and organic impurities.
• Residual solvents and catalysts.
• Heavy metals or elemental impurities.
• Stereochemical composition.
• Microbial quality where applicable.
• Container-closure compatibility.
• Stability and extractables data.
• Good manufacturing practice controls.

The absence of a broad and well-established excipient precedent increases development cost and lengthens customer qualification cycles.

What patents protect 1,2-butanediol?

The base molecule is an established chemical compound and is not a realistic target for new composition-of-matter exclusivity. Commercial patent value is more likely to reside in:

• Catalytic production methods.
• Bio-based fermentation routes.
• Selective separation of stereoisomers.
• Low-impurity purification.
• Polymer and resin applications.
• Pharmaceutical formulations containing the diol.
• Delivery systems using the diol as a solvent or plasticizer.

Patent protection should therefore be evaluated at the process and application level. A patent search limited to the term “1,2-butanediol” will produce a mixed population of expired composition patents, process patents, formulations, and references where the compound is only one option in a large Markush claim.

Are there Orange Book patents or Paragraph IV challenges?

No standalone Orange Book patent or Paragraph IV litigation attaches to 1,2-butanediol as an excipient. The Orange Book lists patents and exclusivity associated with approved drug products, not a general patent estate for an excipient chemical.[4]

Paragraph IV risk could arise only indirectly if a finished pharmaceutical product uses 1,2-butanediol and the product sponsor lists formulation, method-of-use, or delivery-system patents. Any challenge would target the drug product’s listed patents, not the excipient as a standalone commodity.

When does 1,2-butanediol lose exclusivity?

1,2-Butanediol has no conventional pharmaceutical exclusivity clock. It is a mature chemical substance, and any basic compound-level patent protection would generally be historical rather than commercially relevant.

The practical barriers are instead:

• Supplier qualification.
• Proprietary manufacturing know-how.
• Regulatory data packages.
• Customer-specific formulation data.
• Purity and stereochemical control.
• Long-term supply agreements.
• Process patents covering lower-cost or bio-based production.

These barriers can create commercial defensibility without creating legal exclusivity over the molecule.

What manufacturing and supply-chain factors affect pricing?

Production economics are linked to petrochemical feedstocks, especially C4 olefin availability, energy costs, catalyst efficiency, purification yield, and regional logistics. The material may be produced through chemical routes involving oxidation or hydration chemistry, while newer research focuses on bio-based pathways and selective production of diol isomers.[5][6]

The main cost variables are:

Cost variable	Effect on financial trajectory
C4 feedstock prices	Direct effect on production cost
Energy and distillation costs	Significant for high-purity grades
Isomer separation	Raises cost when tight identity control is required
Quality documentation	Increases cost for pharmaceutical customers
Regional freight	Material for low-volume, high-value shipments
Capacity utilization	Determines fixed-cost absorption
Yield and impurity removal	Controls premium-grade margin

A supplier with an integrated feedstock position can compete in industrial markets. A specialty producer with validated purification and regulatory documentation can achieve higher margins in pharmaceutical and cosmetic grades, even at lower volumes.

What is the financial trajectory for 1,2-butanediol?

The likely financial trajectory is gradual and qualification-led rather than volume-led.

Base case

Demand grows slowly as formulators evaluate the material against propylene glycol, glycerin, and 1,3-butanediol. Revenue remains concentrated among specialty suppliers and distributors. Margin depends on purity, documentation, and customer retention rather than broad commodity expansion.

Upside case

Growth accelerates if:

• A major pharmaceutical formulation adopts the material.
• A bio-based manufacturing route reaches commercial scale.
• A supplier demonstrates a clear toxicology or sensory advantage.
• Regulatory precedent expands in topical or oral products.
• Customers seek alternatives to established glycols for supply-chain diversification.

Downside case

The material remains commercially limited if:

• Pharmaceutical qualification costs exceed performance benefits.
• Suppliers cannot provide consistent stereochemical or impurity specifications.
• Propylene glycol and glycerin prices remain competitive.
• Market reports continue to aggregate 1,2- and 1,3-butanediol, obscuring actual demand.
• Regulatory agencies require additional route-specific toxicology data.

No public company appears to report material revenue specifically from 1,2-butanediol. Revenue exposure is therefore indirect through specialty chemicals, ingredients, solvents, and formulation-material portfolios.

Which companies are challenging the market?

The competitive landscape is fragmented across chemical manufacturers, specialty-ingredient suppliers, and laboratory distributors. Publicly visible catalog availability does not establish bulk manufacturing capacity. Companies selling research-grade or small-pack quantities should not be treated as evidence of large-scale pharmaceutical supply.

The most relevant competitive groups are:

• Integrated chemical producers with C4 feedstock access.
• Specialty glycol manufacturers.
• Cosmetic-ingredient suppliers.
• Contract manufacturers capable of custom purification.
• Distributors offering documented pharmaceutical or personal-care grades.
• Biotechnology companies developing bio-based diol routes.

Supplier diligence should verify manufacturing site, annual capacity, change-control history, GMP status, analytical methods, regulatory support, and whether the seller is a producer or distributor.

What generic-entry and biosimilar risks exist?

There is no conventional generic-entry event for 1,2-butanediol itself because it is an excipient rather than an approved reference drug. Biosimilar risk is also not applicable because the molecule is a small synthetic chemical, not a biologic.

Generic substitution risk exists at the formulation level. If a pharmaceutical customer uses 1,2-butanediol as a nonexclusive solvent or humectant, the customer may switch to propylene glycol, glycerin, PEG 400, or 1,3-butanediol without changing the active ingredient. That substitution risk limits pricing power unless the excipient has a demonstrated performance or regulatory advantage.

Key Takeaways

• 1,2-Butanediol is a niche C4 diol, not a broadly commoditized pharmaceutical excipient.
• Market-size estimates require strict separation from 1,3-butanediol and generic “butylene glycol” products.
• Pharmaceutical demand is qualification-driven and likely smaller than cosmetics and industrial demand.
• Propylene glycol, glycerin, 1,3-butanediol, and PEG 400 are the principal substitutes.
• The molecule has no conventional FDA exclusivity, Orange Book position, Paragraph IV exposure, or biosimilar pathway.
• Commercial defensibility depends on purity, manufacturing consistency, regulatory documentation, and customer qualification.
• The strongest upside would come from a major formulation adoption or scalable bio-based production.
• Public financial disclosures do not support a standalone revenue forecast for 1,2-butanediol.

FAQs About 1,2-Butanediol

Is 1,2-butanediol the same as butylene glycol?

No. “Butylene glycol” is an ambiguous commercial term. 1,2-butanediol is CAS 584-03-6, while 1,3-butanediol is CAS 107-88-0. The two isomers should be analyzed separately for regulatory, toxicological, supply, and market purposes.

Is 1,2-butanediol used in injectable drugs?

Broad injectable use should not be assumed. Route-specific safety, impurity, sterility, and toxicology requirements are substantially stricter than for cosmetic or topical use.

Can 1,2-butanediol replace propylene glycol?

It may replace propylene glycol in selected formulations after comparative studies. Replacement requires evaluation of solubility, viscosity, stability, preservative performance, irritation, packaging compatibility, and regulatory acceptability.

Does 1,2-butanediol have a USP-NF monograph?

A supplier or purchaser should verify the current USP-NF compendial status for the exact isomer and grade. Generic references to “butylene glycol” do not establish that a specific 1,2-butanediol product meets a compendial standard.

What is the main investment risk in 1,2-butanediol?

The main risk is demand substitution. Formulators have several established alternatives, so growth depends on documented technical advantages and successful qualification rather than simple expansion of the overall glycol market.

References

1. National Center for Biotechnology Information. (n.d.). PubChem compound summary for CID 8653, 1,2-butanediol. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/1_2-Butanediol

2. National Center for Biotechnology Information. (n.d.). PubChem compound summary for CID 8723, 1,3-butanediol. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/1_3-Butanediol

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. European Chemicals Agency. (n.d.). 1,2-Butanediol substance information. https://echa.europa.eu/

6. Organisation for Economic Co-operation and Development. (n.d.). SIDS initial assessment profile: 1,2-Butanediol. OECD Existing Chemicals Database. https://www.oecd.org/chemicalsafety/biotrac/existingchemicals/